Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 75/100

Failure Rate

21.4%

3 terminated/withdrawn out of 14 trials

Success Rate

62.5%

-24.0% vs industry average

Late-Stage Pipeline

0 trials in Phase 3/4

Results Transparency

20%

1 of 5 completed trials have results

Key Signals

3 recruiting1 with results

Enrollment Performance

Analytics

Phase 2

5(100.0%)

5Total

Phase 2(5)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (14)

Showing 14 of 14 trials

NCT06252675Phase 2Recruiting

Glofitamab With Pirtobrutinib for Relapsed or Refractory Mantle Cell Lymphoma

Role: collaborator

NCT05271630Active Not Recruiting

Multiple Myeloma Outcomes Based on Maintenance Therapy Post Autologous Stem Cell Transplant

Role: collaborator

NCT04419519Phase 2Active Not Recruiting

Assessing Minimal Residual Disease by Next- Generation Sequencing to Minimize Exposure in People With CLL or SLL Who Have Been Treated With Venetoclax

Role: collaborator

NCT06828991Phase 2Recruiting

A Study to Evaluate the Impact of Mosunetuzumab Consolidation for Older Patients With Diffuse Large B-cell Lymphoma (DLBCL) Who Have Detectable Amounts of ctDNA (Circulating Tumor DNA) at the End of Treatment With Pola-R-mini-CHP

Role: collaborator

NCT02553642Phase 2Completed

Relationship Between Tumor Mutation Burden and Predicted Neo-antigen Burden in Patients With Advanced Melanoma or Bladder Cancer Treated With Nivolumab or Nivolumab Plus Ipilimumab (CA209-260)

Role: collaborator

NCT06557330Phase 2Not Yet Recruiting

MRD Guided De-intensification of Bendamustine/Rituximab for Indolent Non-Hodgkin Lymphoma

Role: collaborator

NCT05255354Recruiting

Optimizing ctDNA-based MRD Assessment in DLBCL, MCL, and FL Patients Undergoing CAR Therapy

Role: lead

NCT04545333Terminated

The clonoSEQ® Watch Registry

Role: lead

NCT05769829Terminated

ImmuneSense™ IBD Study